Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michel Bertrand

Showing results (31-40 of 43) with videos related to

Pageof 5
Sort By:
European Heart Journal|January 24, 2009
Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: association with hyperglycaemia, insulin-resistance, adiponectin and plasminogen activator inhibitor-1Frédéric Mouquet, François Cuilleret, Sophie Susen, et al.
Journal of the American College of Cardiology|May 3, 2008
Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trialHarvey D White, Derek P Chew, James W Hoekstra, et al.
International Journal of Cardiology|January 12, 2015
Prediction of absolute risk reduction of cardiovascular events with perindopril for individual patients with stable coronary artery disease - results from EUROPAJoep van der Leeuw, Rohit M Oemrawsingh, Yolanda van der Graaf, et al.
The American Journal of Cardiology|July 17, 2007
Long-term effect of perindopril on coronary atherosclerosis progression (from the perindopril's prospective effect on coronary atherosclerosis by angiography and intravascular ultrasound evaluation [PERSPECTIVE] study)Gastón A Rodriguez-Granillo, Jeroen Vos, Nico Bruining, et al.
Circulation|May 22, 2002
Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET TrialGregg W Stone, David J Moliterno, Michel Bertrand, et al.
JACC. Cardiovascular Interventions|June 25, 2011
Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trialsRoxana Mehran, Stuart Pocock, Eugenia Nikolsky, et al.
European Heart Journal|July 2, 2011
Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failureFabrice Ivanes, Sophie Susen, Frédéric Mouquet, et al.
Archives of Internal Medicine|April 30, 2003
Critical issues in peripheral arterial disease detection and management: a call to actionJill J F Belch, Eric J Topol, Giancarlo Agnelli, et al.
European Heart Journal|June 12, 2010
Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery diseaseJasper Jan Brugts, Aaron Isaacs, Eric Boersma, et al.
Journal of Hypertension|December 16, 2010
A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individualsJasper J Brugts, Aaron Isaacs, Moniek Pm de Maat, et al.
Pageof 5

Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
European Heart Journal|January 24, 2009
Metabolic syndrome and collateral vessel formation in patients with documented occluded coronary arteries: association with hyperglycaemia, insulin-resistance, adiponectin and plasminogen activator inhibitor-1Frédéric Mouquet, François Cuilleret, Sophie Susen, et al.
Journal of the American College of Cardiology|May 3, 2008
Safety and efficacy of switching from either unfractionated heparin or enoxaparin to bivalirudin in patients with non-ST-segment elevation acute coronary syndromes managed with an invasive strategy: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trialHarvey D White, Derek P Chew, James W Hoekstra, et al.
International Journal of Cardiology|January 12, 2015
Prediction of absolute risk reduction of cardiovascular events with perindopril for individual patients with stable coronary artery disease - results from EUROPAJoep van der Leeuw, Rohit M Oemrawsingh, Yolanda van der Graaf, et al.
The American Journal of Cardiology|July 17, 2007
Long-term effect of perindopril on coronary atherosclerosis progression (from the perindopril's prospective effect on coronary atherosclerosis by angiography and intravascular ultrasound evaluation [PERSPECTIVE] study)Gastón A Rodriguez-Granillo, Jeroen Vos, Nico Bruining, et al.
Circulation|May 22, 2002
Impact of clinical syndrome acuity on the differential response to 2 glycoprotein IIb/IIIa inhibitors in patients undergoing coronary stenting: the TARGET TrialGregg W Stone, David J Moliterno, Michel Bertrand, et al.
JACC. Cardiovascular Interventions|June 25, 2011
Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trialsRoxana Mehran, Stuart Pocock, Eugenia Nikolsky, et al.
European Heart Journal|July 2, 2011
Aldosterone, mortality, and acute ischaemic events in coronary artery disease patients outside the setting of acute myocardial infarction or heart failureFabrice Ivanes, Sophie Susen, Frédéric Mouquet, et al.
Archives of Internal Medicine|April 30, 2003
Critical issues in peripheral arterial disease detection and management: a call to actionJill J F Belch, Eric J Topol, Giancarlo Agnelli, et al.
European Heart Journal|June 12, 2010
Genetic determinants of treatment benefit of the angiotensin-converting enzyme-inhibitor perindopril in patients with stable coronary artery diseaseJasper Jan Brugts, Aaron Isaacs, Eric Boersma, et al.
Journal of Hypertension|December 16, 2010
A pharmacogenetic analysis of determinants of hypertension and blood pressure response to angiotensin-converting enzyme inhibitor therapy in patients with vascular disease and healthy individualsJasper J Brugts, Aaron Isaacs, Moniek Pm de Maat, et al.
Pageof 5